IL-32 promotes angiogenesis

Journal of Immunology

Volumn 192, Issue 2, 2014, Pages 589-602

  Nold Petry, Claudia A ^a   Rudloff, Ina ^a   Baumer, Yvonne ^b   Ruvo, Menotti ^c   Marasco, Daniela ^d   Botti, Paolo ^e   Farkas, Laszlo ^f   Cho, Steven X ^a   Zepp, Jarod A ^g   Azam, Tania ^g   Dinkel, Hannah ^g   Palmer, Brent E ^g   Boisvert, William A ^b   Cool, Carlyne D ^g   Taraseviciene Stewart, Laima ^g   Heinhuis, Bas ^h   Joosten, Leo A B ^h   Dinarello, Charles A ^g,h   Voelkel, Norbert F ^g,i   Nold, Marcel F ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF HAWAII   (United States)

^c CNR   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e ArisGen SA   (Switzerland)

^f VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; ENDOSTATIN; GAMMA INTERFERON; GELATINASE B; INTERLEUKIN 32; INTERLEUKIN 32GAMMA; INTERLEUKIN 8; LACTATE DEHYDROGENASE; NITRIC OXIDE; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL XL; SEMAXANIB; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VITRONECTIN RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NEWBORN; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; UMBILICAL VEIN ENDOTHELIAL CELL;

ACTIVINS; ANIMALS; APOPTOSIS; CELLS, CULTURED; ENDOSTATINS; GLIOBLASTOMA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPERTENSION, PULMONARY; INTEGRIN ALPHAVBETA3; INTERFERON-GAMMA; INTERLEUKIN-8; INTERLEUKINS; MATRIX METALLOPROTEINASE 9; MICE; NEOVASCULARIZATION, PATHOLOGIC; NITROGEN OXIDES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84892700407     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202802     Document Type: Article

References (68)

1. Kim, S. H., S. Y. Han, T. Azam, D. Y. Yoon, and C. A. Dinarello. 2005. Interleukin-32: a cytokine and inducer of TNFa. Immunity 22: 131-142.
2. Goda, C., T. Kanaji, S. Kanaji, G. Tanaka, K. Arima, S. Ohno, and K. Izuhara. 2006. Involvement of IL-32 in activation-induced cell death in T cells. Int. Immunol. 18: 233-240. (Pubitemid 43160136)
3. Imaeda, H., A. Andoh, T. Aomatsu, R. Osaki, S. Bamba, O. Inatomi, T. Shimizu, and Y. Fujiyama. 2011. A new isoform of interleukin-32 suppresses IL-8 mRNA expression in the intestinal epithelial cell line HT-29. Mol Med Rep 4: 483-487.
4. Nold-Petry, C. A., M. F. Nold, J. A. Zepp, S. H. Kim, N. F. Voelkel, and C. A. Dinarello. 2009. IL-32-dependent effects of IL-1β on endothelial cell functions. Proc. Natl. Acad. Sci. USA 106: 3883-3888.
5. Heinhuis, B., M. G. Netea, W. B. van den Berg, C. A. Dinarello, and L. A. Joosten. 2012. Interleukin-32: a predominantly intracellular proinflammatory mediator that controls cell activation and cell death. Cytokine 60: 321-327.
6. Heinhuis, B., M. I. Koenders, F. A. van de Loo, M. G. Netea, W. B. van den Berg, and L. A. Joosten. 2011. Inflammation-dependent secretion and splicing of IL-32γ in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 108: 4962-4967.
7. Novick, D., M. Rubinstein, T. Azam, A. Rabinkov, C. A. Dinarello, and S. H. Kim. 2006. Proteinase 3 is an IL-32 binding protein. Proc. Natl. Acad. Sci. USA 103: 3316-3321. (Pubitemid 43346467)
8. Kim, S., S. Lee, E. Her, S. Bae, J. Choi, J. Hong, J. Jaekal, D. Yoon, T. Azam, C. A. Dinarello, and S. Kim. 2008. Proteinase 3-processed form of the recombinant IL-32 separate domain. BMB Rep 41: 814-819.
9. Nold, M. F., C. A. Nold-Petry, G. B. Pott, J. A. Zepp, M. T. Saavedra, S. H. Kim, and C. A. Dinarello. 2008. Endogenous IL-32 controls cytokine and HIV-1 production. J. Immunol. 181: 557-565.
10. Calabrese, F., S. Baraldo, E. Bazzan, F. Lunardi, F. Rea, P. Maestrelli, G. Turato, K. Lokar-Oliani, A. Papi, R. Zuin, et al. 2008. IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 178: 894-901.
11. Dinarello, C. A., and S. H. Kim. 2006. IL-32, a novel cytokine with a possible role in disease. Ann. Rheum. Dis. 65(Suppl. 3): iii61-iii64. (Pubitemid 44629106)
12. Jeong, H. J., S. Y. Shin, H. A. Oh, M. H. Kim, J. S. Cho, and H. M. Kim. 2011. IL-32 up-regulation is associated with inflammatory cytokine production in allergic rhinitis. J. Pathol. 224: 553-563.
13. Na, S. J., S. H. So, K. O. Lee, and Y. C. Choi. 2011. Elevated serum level of interleukin-32α in the patients with myasthenia gravis. J. Neurol. 258: 1865-1870.
14. Cagnard, N., F. Letourneur, A. Essabbani, V. Devauchelle, S. Mistou, A. Rapinat, C. Decraene, C. Fournier, and G. Chiocchia. 2005. Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. Eur. Cytokine Netw. 16: 289-292. (Pubitemid 350056544)
15. Joosten, L. A., M. G. Netea, S. H. Kim, D. Y. Yoon, B. Oppers-Walgreen, T. R. Radstake, P. Barrera, F. A. van de Loo, C. A. Dinarello, and W. B. van den Berg. 2006. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 103: 3298-3303. (Pubitemid 43346464)
16. Zepp, J. A., C. A. Nold-Petry, C. A. Dinarello, and M. F. Nold. 2011. Protection from RNA and DNA viruses by IL-32. J. Immunol. 186: 4110-4118.
17. Li, W., W. Sun, L. Liu, F. Yang, Y. Li, Y. Chen, J. Fang, W. Zhang, J. Wu, and Y. Zhu. 2010. IL-32: a host proinflammatory factor against influenza viral replication is upregulated by aberrant epigenetic modifications during influenza A virus infection. J. Immunol. 185: 5056-5065.
18. Pan, X., H. Cao, J. Lu, X. Shu, X. Xiong, X. Hong, Q. Xu, H. Zhu, G. Li, and G. Shen. 2011. Interleukin-32 expression induced by hepatitis B virus protein X is mediated through activation of NF-kB. Mol. Immunol. 48: 1573-1577.
19. Moschen, A. R., T. Fritz, A. D. Clouston, I. Rebhan, O. Bauhofer, H. D. Barrie, E. E. Powell, S. H. Kim, C. A. Dinarello, R. Bartenschlager, et al. 2011. Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virusrelated liver inflammation and fibrosis. Hepatology 53: 1819-1829.
20. Lee, S., J. H. Kim, H. Kim, J. W. Kang, S. H. Kim, Y. Yang, J. Kim, J. Park, S. Park, J. Hong, and D. Y. Yoon. 2011. Activation of the interleukin-32 proinflammatory pathway in response to human papillomavirus infection and overexpression of interleukin-32 controls the expression of the human papillomavirus oncogene. Immunology 132: 410-420.
21. Nishimoto, K. P., A. K. Laust, and E. L. Nelson. 2008. A human dendritic cell subset receptive to the Venezuelan equine encephalitis virus-derived replicon particle constitutively expresses IL-32. J. Immunol. 181: 4010-4018.
22. Marcondes, A. M., A. J. Mhyre, D. L. Stirewalt, S. H. Kim, C. A. Dinarello, and H. J. Deeg. 2008. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc. Natl. Acad. Sci. USA 105: 2865-2870. (Pubitemid 351723635)
23. Nishida, A., A. Andoh, O. Inatomi, and Y. Fujiyama. 2009. Interleukin-32 expression in the pancreas. J. Biol. Chem. 284: 17868-17876.
24. Sorrentino, C., and E. Di Carlo. 2009. Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am. J. Respir. Crit. Care Med. 180: 769-779.
25. Oh, J. H., M. C. Cho, J. H. Kim, S. Y. Lee, H. J. Kim, E. S. Park, J. O. Ban, J. W. Kang, D. H. Lee, J. H. Shim, et al. 2011. IL-32γ inhibits cancer cell growth through inactivation of NF-kB and STAT3 signals. Oncogene 30: 3345-3359.
26. Ciccia, F., R. Alessandro, A. Rizzo, S. Principe, F. Raiata, A. Cavazza, G. Guggino, A. Accardo-Palumbo, L. Boiardi, A. Ferrante, et al. 2011. Expression of IL-32 in the inflamed arteries of patients with giant cell arteritis. Arthritis Rheum. 63: 2097-2104.
27. Heinhuis, B., M. I. Koenders, W. B. van den Berg, M. G. Netea, C. A. Dinarello, and L. A. Joosten. 2012. Interleukin 32 (IL-32) contains a typical a-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1. J. Biol. Chem. 287: 5733-5743.
28. Cool, C. D., J. S. Stewart, P. Werahera, G. J. Miller, R. L. Williams, N. F. Voelkel, and R. M. Tuder. 1999. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am. J. Pathol. 155: 411-419. (Pubitemid 29370391)
29. Hassoun, P. M., L. Mouthon, J. A. Barberà, S. Eddahibi, S. C. Flores, F. Grimminger, P. L. Jones, M. L. Maitland, E. D. Michelakis, N. W. Morrell, et al. 2009. Inflammation, growth factors, and pulmonary vascular remodeling. J. Am. Coll. Cardiol. 54(1, Suppl.): S10-S19.
30. Nicolls, M. R., L. Taraseviciene-Stewart, P. R. Rai, D. B. Badesch, and N. F. Voelkel. 2005. Autoimmunity and pulmonary hypertension: a perspective. Eur. Respir. J. 26: 1110-1118. (Pubitemid 41829945)
31. Tuder, R. M., B. Groves, D. B. Badesch, and N. F. Voelkel. 1994. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am. J. Pathol. 144: 275-285. (Pubitemid 24165948)
32. Humbert, M., G. Monti, F. Brenot, O. Sitbon, A. Portier, L. Grangeot-Keros, P. Duroux, P. Galanaud, G. Simonneau, and D. Emilie. 1995. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 151: 1628-1631.
33. Tuder, R. M., and N. F. Voelkel. 1998. Pulmonary hypertension and inflammation. J. Lab. Clin. Med. 132: 16-24. (Pubitemid 28329606)
34. Voelkel, N. F., J. G. Gomez-Arroyo, A. Abbate, H. J. Bogaard, and M. R. Nicolls. 2012. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur. Respir. J. 40: 1555-1565.
35. Tuder, R. M., M. Chacon, L. Alger, J. Wang, L. Taraseviciene-Stewart, Y. Kasahara, C. D. Cool, A. E. Bishop, M. Geraci, G. L. Semenza, et al. 2001. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J. Pathol. 195: 367-374.
36. Canavese, M., F. Altruda, T. Ruzicka, and J. Schauber. 2010. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis: a possible target for novel therapies? J. Dermatol. Sci. 58: 171-176.
37. Hackeng, T. M., J. A. Fernández, P. E. Dawson, S. B. Kent, and J. H. Griffin. 2000. Chemical synthesis and spontaneous folding of a multidomain protein: anticoagulant microprotein S. Proc. Natl. Acad. Sci. USA 97: 14074-14078. (Pubitemid 32016532)
38. Nold, M. F., C. A. Nold-Petry, J. A. Zepp, B. E. Palmer, P. Bufler, and C. A. Dinarello. 2010. IL-37 is a fundamental inhibitor of innate immunity. Nat. Immunol. 11: 1014-1022.
39. Sakao, S., L. Taraseviciene-Stewart, J. D. Lee, K. Wood, C. D. Cool, and N. F. Voelkel. 2005. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J. 19: 1178-1180. (Pubitemid 40946457)
40. Humbert, M., N. W. Morrell, S. L. Archer, K. R. Stenmark, M. R. MacLean, I. M. Lang, B. W. Christman, E. K. Weir, O. Eickelberg, N. F. Voelkel, and M. Rabinovitch. 2004. Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43(12, Suppl. 5): 13S-24S. (Pubitemid 38759713)
41. Voronov, E., D. S. Shouval, Y. Krelin, E. Cagnano, D. Benharroch, Y. Iwakura, C. A. Dinarello, and R. N. Apte. 2003. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. USA 100: 2645-2650. (Pubitemid 36297552)
42. Carmi, Y., E. Voronov, S. Dotan, N. Lahat, M. A. Rahat, M. Fogel, M. Huszar, M. R. White, C. A. Dinarello, and R. N. Apte. 2009. The role of macrophagederived IL-1 in induction and maintenance of angiogenesis. J. Immunol. 183: 4705-4714.
43. Baumer, Y., B. Scholz, S. Ivanov, and B. Schlosshauer. 2011. Telomerase-based immortalization modifies the angiogenic/inflammatory responses of human coronary artery endothelial cells. Exp. Biol. Med. (Maywood) 236: 692-700.
44. Wang, W., Y. L. Wang, X. Y. Chen, Y. T. Li, W. Hao, Y. P. Jin, and B. Han. 2011. Dexamethasone attenuates development of monocrotaline-induced pulmonary arterial hypertension. Mol. Biol. Rep. 38: 3277-3284.
45. Wort, S. J., M. Ito, P. C. Chou, S. K. Mc Master, R. Badiger, E. Jazrawi, P. de Souza, T. W. Evans, J. A. Mitchell, L. Pinhu, et al. 2009. Synergistic induction of endothelin-1 by tumor necrosis factor alpha and interferon γ is due to enhanced NF-kappaB binding and histone acetylation at specific kB sites. J. Biol. Chem. 284: 24297-24305.
46. Lee, M. S., and N. Sarvetnick. 1994. Induction of vascular addressins and adhesion molecules in the pancreas of IFN-γ transgenic mice. J. Immunol. 152: 4597-4603. (Pubitemid 24134419)
47. Westphal, J. R., H. W. Willems, W. J. Tax, R. A. Koene, D. J. Ruiter, and R. M. de Waal. 1993. The proliferative response of human T cells to allogeneic IFN-γ-treated endothelial cells is mediated via both CD2/LFA-3 and LFA-1/ICAM-1 and-2 adhesion pathways. Transpl. Immunol. 1: 183-191. (Pubitemid 2020148)
48. Farkas, L., J. Gauldie, N. F. Voelkel, and M. Kolb. 2011. Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis and growth factors. Am. J. Respir. Cell Mol. Biol. 45: 1-15.
49. Matsuo, Y., H. Sawai, N. Ochi, A. Yasuda, H. Takahashi, H. Funahashi, H. Takeyama, and S. Guha. 2009. Interleukin-1alpha secreted by pancreatic cancer cells promotes angiogenesis and its therapeutic implications. J. Surg. Res. 153: 274-281.
50. Shi, C. S., G. Y. Shi, Y. S. Chang, H. S. Han, C. H. Kuo, C. Liu, H. C. Huang, Y. J. Chang, P. S. Chen, and H. L. Wu. 2005. Evidence of human thrombomodulin domain as a novel angiogenic factor. Circulation 111: 1627-1636. (Pubitemid 40525162)
51. Waugh, D. J., and C. Wilson. 2008. The interleukin-8 pathway in cancer. Clin. Cancer Res. 14: 6735-6741.
52. Rai, P. R., C. D. Cool, J. A. King, T. Stevens, N. Burns, R. A. Winn, M. Kasper, and N. F. Voelkel. 2008. The cancer paradigm of severe pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 178: 558-564.
53. Soon, E., A. M. Holmes, C. M. Treacy, N. J. Doughty, L. Southgate, R. D. Machado, R. C. Trembath, S. Jennings, L. Barker, P. Nicklin, et al. 2010. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122: 920-927.
54. Kempuraj, D., P. Conti, M. Vasiadi, K. D. Alysandratos, M. Tagen, D. Kalogeromitros, T. Kourelis, S. Gregoriou, M. Makris, N. G. Stavrianeas, and T. C. Theoharides. 2010. IL-32 is increased along with tryptase in lesional psoriatic skin and is up-regulated by substance P in human mast cells. Eur. J. Dermatol. 20: 865-867.
55. Kobayashi, H., and P. C. Lin. 2009. Molecular characterization of IL-32 in human endothelial cells. Cytokine 46: 351-358.
56. Shchors, K., E. Shchors, F. Rostker, E. R. Lawlor, L. Brown-Swigart, and G. I. Evan. 2006. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev. 20: 2527-2538. (Pubitemid 44396838)
57. Salven, P., K. Hattori, B. Heissig, and S. Rafii. 2002. Interleukin-1α promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J. 16: 1471-1473.
58. Nazarenko, I., R. Marhaba, E. Reich, E. Voronov, M. Vitacolonna, D. Hildebrand, E. Elter, M. Rajasagi, R. N. Apte, and M. Zöller. 2008. Tumorigenicity of IL-1αand IL-1β-deficient fibrosarcoma cells. Neoplasia 10: 549-562. (Pubitemid 351770299)
59. Rüegg, C., O. Dormond, and A. Foletti. 2002. Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target? Endothelium 9: 151-160. (Pubitemid 35021585)
60. Cabrita, M. A., L. M. Jones, J. L. Quizi, L. A. Sabourin, B. C. McKay, and C. L. Addison. 2011. Focal adhesion kinase inhibitors are potent anti-angiogenic agents. Mol. Oncol. 5: 517-526.
61. Shen, T. L., A. Y. Park, A. Alcaraz, X. Peng, I. Jang, P. Koni, R. A. Flavell, H. Gu, and J. L. Guan. 2005. Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J. Cell Biol. 169: 941-952. (Pubitemid 41002870)
62. 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 6: 105-119. (Pubitemid 38173862)
63. Al Husseini, A., G. Bagnato, L. Farkas, J. Gomez-Arroyo, D. Farkas, S. Mizuno, D. Kraskauskas, A. Abbate, D. B. Van Tassel Pharm, N. F. Voelkel, and H. J. Bogaard. 2012. Thyroid hormone is highly permissive in angioproliferative pulmonary hypertension in rats. Eur. Respir. J. 41: 104-114.
64. Moldenhauer, A., M. Futschik, H. Lu, M. Helmig, P. Götze, G. Bal, M. Zenke, W. Han, and A. Salama. 2011. Interleukin 32 promotes hematopoietic progenitor expansion and attenuates bone marrow cytotoxicity. Eur. J. Immunol. 41: 1774-1786.
65. Kobayashi, H., J. Huang, F. Ye, Y. Shyr, T. S. Blackwell, and P. C. Lin. 2010. Interleukin-32b propagates vascular inflammation and exacerbates sepsis in a mouse model. PLoS ONE 5: e9458.
66. Kobayashi, H., E. M. Yazlovitskaya, and P. C. Lin. 2009. Interleukin-32 positively regulates radiation-induced vascular inflammation. Int. J. Radiat. Oncol. Biol. Phys. 74: 1573-1579.
67. Cho, K. A., Y. H. Jun, J. W. Suh, J. S. Kang, H. J. Choi, and S. Y. Woo. 2010. Orientia tsutsugamushi induced endothelial cell activation via the NOD1-IL-32 pathway. Microb. Pathog. 49: 95-104.
68. Meyer, N., J. Christoph, H. Makrinioti, P. Indermitte, C. Rhyner, M. Soyka, T. Eiwegger, M. Chalubinski, K. Wanke, H. Fujita, et al. 2012. Inhibition of angiogenesis by IL-32: possible role in asthma. J. Allergy Clin. Immunol. 129: 964-973.e7.